Montana passed SB535, a biotech law allowing physicians to administer experimental treatments outside trials if they completed FDA Phase 1, received approval from a state review board, and are delivered at licensed clinics with enhanced consent. The law uniquely permits sponsors and clinics to charge for treatment, addressing the "Valley of Death" funding gap where promising drugs stall between early trials and commercial investment.